サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1405864

過活動膀胱治療の市場規模・シェア・動向分析レポート：タイプ別、疾患タイプ別、流通チャネル別、地域別、セグメント予測、2024年～2030年

Overactive Bladder Treatment Market Size, Share & Trends Analysis Report, By Type (Anticholinergics, Mirabegron, Neuromodulation, Botox), By Disease Type (Idiopathic, Neurogenic), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 100 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
過活動膀胱治療の市場規模・シェア・動向分析レポート：タイプ別、疾患タイプ別、流通チャネル別、地域別、セグメント予測、2024年～2030年
出版日: 2023年12月15日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

過活動膀胱治療市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、過活動膀胱治療の世界市場規模は2030年までに52億5,000万米ドルに達すると予測され、予測期間中のCAGRは4.8%と推定・予測されています。

過活動膀胱（OAB）状態に対する意識の高まりや、この疾患に対する新規製剤を開発するための研究開発投資の増加などの要因が、世界市場を牽引すると予測されています。さらに、過活動膀胱治療薬や治療法に対する高い需要に起因する競合の高まりや、大手企業による医薬品製造への重点化の高まりも、需要を前進させる重要な要因です。

OABや尿失禁に対する人々の意識の高まりは、市場の成長を後押しする主な要因の一つです。業界を運営する様々な主要企業は、過活動膀胱の状態についての認識を高めるために数多くの取り組みを行っています。例えば、2023年1月、市場で事業を展開する主要企業であるUrovant Sciences社は、女優であり患者でもあるHolly Robinson Peete氏と協力し、OABに対する認識を高めるキャンペーンを実施しました。このようなイニシアチブは、治療の選択肢に関する認識と知識を高め、それによって治療法の採用を増加させるのに役立ちます。

さらに、OABをターゲットとした革新的な製剤や治療法を開発するための投資の増加は、予測期間中の成長を促進すると予測されています。例えば、2019年11月、新興企業であるEBT Medical, Inc.は、過活動膀胱を治療するための非侵襲的神経調節技術を開発するためにシリーズAで1,000万米ドルの資金提供を受けた。このように、薬や治療に焦点を当てた開発や投資は、地理的な拡大を促進すると予想されています。

さらに、業界参入企業は、この競争の激しい市場での地位を維持するために、提携や新製品の発売など、さまざまな戦略に取り組んでいます。例えば、2023年3月、杏林製薬株式会社は住友製薬株式会社と提携し、台湾およびシンガポール、香港、インドネシア、ベトナムなどのアジア諸国におけるOAB治療薬Vibegronの開発、製造、商業化を開始しました。このような大手企業間の提携により、各国における医薬品や治療法へのアクセスが向上し、今後数年間の成長がさらに促進されることが期待されます。

過活動膀胱治療市場レポートハイライト

  • ミラベグロン製剤が2023年の市場を席巻。これは、OAB治療にミラベグロン製剤が高い採用率と処方率を示したことに起因します。
  • 疾患タイプ別では、特発性過活動膀胱は有病率が高いため、2023年の業界売上高に最も貢献しました。
  • 流通チャネルでは、小売薬局が市場を独占しました。高い収益成長は、OAB治療薬を提供する確立された小売薬局の存在と患者適合性の高さに起因します。
  • 北米は、Pfizer, Inc.、AbbVie, Inc.、Viatris, Inc.などの主要企業が同地域に存在するため、2023年の過活動膀胱治療市場を独占しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場変数、動向、および範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 業界分析ツール
    • ポーターのファイブフォース分析
    • PESTEL分析
    • COVID-19感染症の影響分析

第4章 タイプのビジネス分析

  • 過活動膀胱治療市場：タイプの変動分析
  • 抗コリン薬
  • ミラベグロン
  • ボトックス
  • 神経調節
  • その他

第5章 疾患タイプのビジネス分析

  • 過活動膀胱治療市場：疾患タイプの変動分析
  • 特発性過活動膀胱
  • 神経因性過活動膀胱

第6章 流通チャネルのビジネス分析

  • 過活動膀胱治療市場：流通チャネルの変動分析
  • 病院薬局
  • 小売薬局
  • その他

第7章 地域のビジネス分析

  • 地域別の過活動膀胱治療市場シェア、2023年および2030年
  • 北米
    • 北米過活動膀胱治療市場、2018年～2030年
    • 米国
    • カナダ
  • 欧州
    • 欧州過活動膀胱治療市場、2018年～2030年
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋地域
    • アジア太平洋地域の過活動膀胱治療市場、2018～2030年
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ラテンアメリカの過活動膀胱治療市場、2018年から2030年
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • MEA過活動膀胱治療市場、2018年～2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 企業の分類
  • 戦略マッピング
  • 企業の市場シェア分析、2023年
  • 企業プロファイル・一覧表
    • Pfizer, Inc
    • AbbVie Inc.
    • Astellas Pharma Inc.
    • Medtronic
    • Sumitomo Pharma America, Inc.（Urovant Sciences.）
    • Viatris Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Hisamitsu Pharmaceutical Co., Inc.
    • Macleods Pharmaceuticals Ltd.
    • Endo International plc
図表

List of Tables

  • TABLE 1 List of Secondary Sources
  • TABLE 2 List of Abbreviations
  • TABLE 3 Global Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 4 Global Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 5 Global Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 6 Global Overactive Bladder Treatment Market, By Region, 2018 - 2030 (USD Million)
  • TABLE 7 North America Overactive Bladder Treatment Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 8 North America Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 9 North America Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 10 North America Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 11 U.S. Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 12 U.S. Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 13 U.S. Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 14 Canada Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 15 Canada Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 16 Canada Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 17 Europe Overactive Bladder Treatment Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 18 Europe Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 19 Europe Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 20 Europe Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 21 UK Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 22 UK Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 23 UK Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 24 Germany Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 25 Germany Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 26 Germany Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 27 France Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 28 France Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 29 France Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 30 Spain Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 31 Spain Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 32 Spain Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 33 Italy Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 34 Italy Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 35 Italy Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 36 Denmark Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 37 Denmark Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 38 Denmark Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 39 Norway Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 40 Norway Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 41 Norway Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 42 Sweden Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 43 Sweden Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 44 Sweden Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 45 Asia Pacific Overactive Bladder Treatment Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 46 Asia Pacific Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 47 Asia Pacific Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 48 Asia Pacific Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 49 China Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 50 China Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 51 China Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 52 Japan Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 53 Japan Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 54 Japan Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 55 India Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 56 India Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 57 India Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 58 South Korea Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 59 South Korea Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 60 South Korea Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 61 Australia Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 62 Australia Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 63 Australia Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 64 Thailand Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 65 Thailand Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 66 Thailand Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 67 Latin America Overactive Bladder Treatment Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 68 Latin America Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 69 Latin America Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 70 Latin America Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 71 Brazil Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 72 Brazil Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 73 Brazil Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 74 Mexico Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 75 Mexico Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 76 Mexico Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 77 Argentina Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million),
  • TABLE 78 Argentina Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 79 Argentina Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 80 MEA Overactive Bladder Treatment Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 81 MEA Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 82 MEA Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 83 MEA Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 84 South Africa Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 85 South Africa Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 86 South Africa Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 87 UAE Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 88 UAE Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 89 UAE Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 90 Saudi Arabia Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million),
  • TABLE 91 Saudi Arabia Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 92 Saudi Arabia Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 93 Kuwait Overactive Bladder Treatment Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 94 Kuwait Overactive Bladder Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • TABLE 95 Kuwait Overactive Bladder Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Overactive bladder treatment market segmentation
  • Fig. 8 Market snapshot, 2023
  • Fig. 9 Market trends & outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 PESTEL analysis
  • Fig. 13 Porter's five forces analysis
  • Fig. 14 Global overactive bladder treatment market: Type outlook and key takeaways
  • Fig. 15 Global overactive bladder treatment market: Type movement analysis
  • Fig. 16 Global overactive bladder treatment market, for anticholinergics, 2018 - 2030 (USD Million)
  • Fig. 17 Global overactive bladder treatment market, for mirabegron, 2018 - 2030 (USD Million)
  • Fig. 18 Global overactive bladder treatment market, for Botox, 2018 - 2030 (USD Million)
  • Fig. 19 Global overactive bladder treatment market, for neuromodulation, 2018 - 2030 (USD Million)
  • Fig. 20 Global overactive bladder treatment market, for other types, 2018 - 2030 (USD Million)
  • Fig. 21 Global overactive bladder treatment market: Disease type outlook and key takeaways
  • Fig. 22 Global overactive bladder treatment market: Disease type movement analysis
  • Fig. 23 Global overactive bladder treatment market, for idiopathic overactive bladder, 2018 - 2030 (USD Million)
  • Fig. 24 Global overactive bladder treatment market, for neurogenic overactive bladder, 2018 - 2030 (USD Million)
  • Fig. 25 Global overactive bladder treatment market: Distribution channel outlook and key takeaways
  • Fig. 26 Global overactive bladder treatment market: Distribution channel movement analysis
  • Fig. 27 Global overactive bladder treatment market, for hospital pharmacy, 2018 - 2030 (USD Million)
  • Fig. 28 Global overactive bladder treatment market, for retail pharmacy, 2018 - 2030 (USD Million)
  • Fig. 29 Global overactive bladder treatment market, for others, 2018 - 2030 (USD Million)
  • Fig. 30 Regional marketplace: Key takeaways
  • Fig. 31 Regional outlook, 2022 & 2030
  • Fig. 32 Global overactive bladder treatment market: Region movement analysis
  • Fig. 33 North America overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 34 U.S overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 35 Canada overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 36 Europe overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 37 Germany overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 38 U.K overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 39 France overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 40 Italy overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 41 Spain overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 42 Denmark overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 43 Sweden overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 44 Norway overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 45 Asia Pacific overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 46 Japan overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 47 China overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 48 India overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 49 Australia overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 50 South Korea overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 51 Thailand overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 52 Latin America overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 53 Brazil overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 54 Mexico overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 55 Argentina overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 56 Middle East and Africa overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 57 South Africa overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 58 Saudi Arabia overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 59 UAE overactive bladder treatment market, 2018 - 2030 (USD Million)
  • Fig. 60 Kuwait overactive bladder treatment market, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68040-168-0

Overactive Bladder Treatment Market Growth & Trends:

The global overactive bladder treatment market size is expected to reach USD 5.25 billion by 2030, and is estimated to register a CAGR of 4.8% over the forecast period, according to a new report by Grand View Research, Inc. Factors such as the growing awareness about the overactive bladder (OAB) condition, along with rising R&D investments to develop novel formulations for this disease, are projected to drive the global market. In addition, rising competition owing to high demand for OAB medications and treatments and rising emphasis of major players to manufacture drugs is another vital factor propelling the demand forward.

Rising awareness about OAB and urinary incontinence among the population is one of the major factors bolstering the growth of the market. Various key players operating in the industry undertake numerous initiatives to raise awareness about the overactive bladder condition. For instance, in January 2023, Urovant Sciences, a key player operating in the market, collaborated with actress and patient Holly Robinson Peete under a campaign to bring awareness to OAB. Such initiatives help increase awareness and knowledge about the treatment options thereby increasing treatment adoption.

Moreover, increasing investments to develop innovative formulations and treatments targeting OAB are anticipated to fuel growth over the forecast period. For instance, in November 2019, EBT Medical, Inc., a startup, received funding of USD 10 million in series A for developing noninvasive neuromodulation technology to treat overactive bladder. Thus, developments and investments focusing on medications and treatments are anticipated to fuel the geographic expansion.

Furthermore, industry participants are undertaking various strategies like collaborations and new product launches to maintain their position in this competitive market. For instance, in March 2023, KYORIN Pharmaceutical Co., Ltd. collaborated with Sumitomo Pharma Co., Ltd. to develop, manufacture, and commercialize Vibegron for OAB in Taiwan and other Asian Countries like Singapore, Hong Kong, Indonesia, and Vietnam. Such collaborations among major players are expected to increase the accessibility of drugs and treatments across the countries, which can further propel growth in the coming years.

Overactive Bladder Treatment Market Report Highlights:

  • Mirabegron drug dominated the market in 2023 with a which can be attributed to the high adoption and prescription rate of Mirabegron for treating OAB
  • Among disease-type segments, the idiopathic overactive bladder segment was the largest revenue contributor for the industry in 2023 due to its high prevalence rate
  • In the distribution channel segment, the retail pharmacies dominated the market. The higher revenue growth is attributed to the presence of established retail pharmacies offering OAB drugs and its better patient compatibility
  • North America dominated the market for overactive bladder treatment in 2023 owing to the presence of key players such as Pfizer, Inc., AbbVie, Inc., and Viatris, Inc. across the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Segment Definitions
    • 1.1.1. Product Segment
    • 1.1.2. Strength Segment
    • 1.1.3. Distribution Channel Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. Gvr's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations
  • 1.12. Research Assumptions

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of target diseases
      • 3.2.1.2. Rising R&D investments for introducing new treatments
      • 3.2.1.3. Growing awareness about the condition
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Adverse effects associated with medications and treatment.
      • 3.2.2.2. Increasing product recalls
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Type Business Analysis

  • 4.1. Overactive Bladder Treatment Market: Type Movement Analysis
  • 4.2. Anticholinergics
    • 4.2.1. Anticholinergics Market, 2018 - 2030 (USD Million)
  • 4.3. Mirabegron
    • 4.3.1. Mirabegron Market, 2018 - 2030 (USD Million)
  • 4.4. Botox
    • 4.4.1. Botox Market, 2018 - 2030 (USD Million)
  • 4.5. Neuromodulation
    • 4.5.1. Neuromodulation Market, 2018 - 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Other Types Market, 2018 - 2030 (USD Million)

Chapter 5. Disease Type Business Analysis

  • 5.1. Overactive Bladder Treatment Market: Disease Type Movement Analysis
  • 5.2. Idiopathic Overactive Bladder
    • 5.2.1. Idiopathic Overactive Bladder Market, 2018 - 2030 (USD Million)
  • 5.3. Neurogenic Overactive Bladder
    • 5.3.1. Neurogenic Overactive Bladder Market, 2018 - 2030 (USD Million)

Chapter 6. Distribution Channel Business Analysis

  • 6.1. Overactive Bladder Treatment Market: Distribution Channel Movement Analysis
  • 6.2. Hospital Pharmacies
    • 6.2.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.3. Retail Pharmacies
    • 6.3.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.4. Others
    • 6.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Overactive Bladder Treatment Market Share By Region, 2023 & 2030
  • 7.2. North America
    • 7.2.1. North America Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Competitive Scenario
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Reimbursement Scenario
      • 7.2.2.5. U.S. Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Competitive Scenario
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Reimbursement Scenario
      • 7.2.3.5. Canada Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Reimbursement Scenario
      • 7.3.2.5. UK Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Reimbursement Scenario
      • 7.3.3.5. Germany Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Reimbursement Scenario
      • 7.3.4.5. France Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Competitive Scenario
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Reimbursement Scenario
      • 7.3.5.5. Italy Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Competitive Scenario
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Reimbursement Scenario
      • 7.3.6.5. Spain Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Competitive Scenario
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Reimbursement Scenario
      • 7.3.7.5. Denmark Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Competitive Scenario
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Reimbursement Scenario
      • 7.3.8.5. Sweden Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Competitive Scenario
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Reimbursement Scenario
      • 7.3.9.5. Norway Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Scenario
      • 7.4.2.5. Japan Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Scenario
      • 7.4.3.5. China Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Scenario
      • 7.4.4.5. India Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Reimbursement Scenario
      • 7.4.5.5. Australia Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.6. Thailand
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Reimbursement Scenario
      • 7.4.6.5. Thailand Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.7. South Korea
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Reimbursement Scenario
      • 7.4.7.5. South Korea Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Scenario
      • 7.5.2.5. Brazil Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Scenario
      • 7.5.3.5. Mexico Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.5.4. Argentina
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Scenario
      • 7.5.4.5. Argentina Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Scenario
      • 7.6.2.5. South Africa Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Scenario
      • 7.6.3.5. Saudi Arabia Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Scenario
      • 7.6.4.5. UAE Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Scenario
      • 7.6.5.5. Kuwait Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Share Analysis, 2023
  • 8.4. Company Profiles/Listing
    • 8.4.1. Pfizer, Inc
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. AbbVie Inc.
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. Astellas Pharma Inc.
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. Medtronic
      • 8.4.4.1. Overview
      • 8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. Sumitomo Pharma America, Inc.( Urovant Sciences.)
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. Viatris Inc.
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. Teva Pharmaceutical Industries Ltd.
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. Hisamitsu Pharmaceutical Co., Inc.
      • 8.4.8.1. Overview
      • 8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Strategic Initiatives
    • 8.4.9. Macleods Pharmaceuticals Ltd.
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. Endo International plc
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Strategic Initiatives